Oncolytics Biotech Inc. Reports Pelareorep Tumor Microenvironment Data

What Happened
On September 29, 2026, Oncolytics Biotech Inc. (ONCY) filed an 8-K (Item 8.01) to announce a press release describing data—published in the Proceedings of the National Academy of Sciences (PNAS)—showing that pelareorep can shift the tumor microenvironment from immunologically inactive to active in hepatocellular carcinoma (HCC). The filing includes the press release as an exhibit and was signed by Kirk Look, Chief Financial Officer, on September 29, 2026. The 8-K does not report earnings, revenue, or other financial results.

Key Details

• Filing date: September 29, 2026 (Form 8-K, Item 8.01: Other Events).
• Subject: Press release reporting PNAS-published data on pelareorep in hepatocellular carcinoma (HCC).
• Exhibit: Press release included as Exhibit 99.1 to the 8-K.
• Signed by: Kirk Look, Chief Financial Officer, on September 29, 2026.

Why It Matters
The 8-K highlights published scientific data that the company says demonstrates a potential mechanism of action for pelareorep in liver cancer—moving tumors from an immunologically “cold” to “hot” state. For investors, this is a non-financial operational update that signals scientific progress and may be relevant to assessing the company’s clinical development trajectory and upcoming milestones. The filing itself does not provide financial metrics, trial outcomes beyond the PNAS report, or definitive commercial implications.